Visalytics
Visalytics
approved EB-1A RFE Issued

Principal Scientist

Pharmaceutical Sciences · India · 2025-09-18

Processing Time
116 days
Decision Date
2025-09-18
Location
Massachusetts
This case is from a publicly available case study. Case studies tend to feature successful outcomes and may not reflect the full range of petition results.

Framework Evaluation

3 of 3 criteria met
Scholarly Articles (Met)

The petitioner authored 14 peer-reviewed journal articles and 4 book chapters in high-impact pharmaceutical venues.

Judging (Met)

The petitioner completed at least 21 peer reviews for selective and high-impact journals in the field.

Original Contributions (Met)

The petitioner's innovations in drug delivery systems, evidenced by nearly 2,000 citations and a patent, represent contributions of major significance.

Why This Petition Was Approved

The petition was approved based on a strong scholarly record including 14 journal articles and 1,966 citations, placing the applicant in the top 1% of the field. Additional evidence included 21 peer-review assignments for high-impact journals and a first-authored patent, satisfying the EB-1A criteria for scholarly articles, judging, and original contributions.

Request for Evidence (RFE)

Successfully Addressed

The case faced an RFE challenging the extraordinary ability of the candidate, which was addressed by providing detailed evidence of the petitioner's research impact and expert testimonials. The response successfully demonstrated that the petitioner's work in oncology and autoimmune diseases met the high standard for EB-1A.

RFE Targets
Original Contributions

Evidence

Evidence Types
Peer Reviewed Publications
Citations
Patents
Reference Letters Independent
Grants
Conference Presentations
Judging Experience
Original Contributions
Evidence Submitted
  • 14 peer-reviewed journal articles (6 first- or co-first-authored)
  • 1,966 citations
  • 21 peer review instances for selective journals
  • 1 first-authored patent and 1 PCT application
  • 4 book chapters (3 first-authored)
  • 1 peer-reviewed conference article and 8 abstracts
  • Development of targeted liposomal delivery of resveratrol for glioblastoma

Similar Cases

Scientist

Pharmaceuticals · India

WeGreened EB-1A approved
Massachusetts 410 days 2025-10-06
The petition was approved based on the petitioner's authorship of 27 peer-reviewed articles and 17 abstracts, which garnered 485 citations from researchers in over 40 countries. His work ranked in the top 10% of most-cited publications in pharmacology for several years. Additionally, he completed over 60 peer reviews and received research grants from the NIH and the National Research Foundation of South Korea.
View Case

Scientist

Pharmaceuticals · India

WeGreened EB-1A approved
California 35 days 2025-11-21
The petition was approved based on a record of 21 peer-reviewed journal articles and 3 patents reflecting commercially relevant innovations. The petitioner demonstrated significant global influence through 1,189 citations and established professional standing by completing 128 peer reviews for scientific journals. These metrics satisfied the EB-1A criteria for scholarly articles, original contributions, and judging.
View Case

Scientist

Pharmaceuticals · China

WeGreened EB-1A approved
Massachusetts 21 days 2025-05-29
The petition was approved based on the satisfaction of at least three EB-1A criteria: authorship of scholarly articles, participation as a judge of the work of others, and original scientific contributions of major significance. Specific metrics included 8 peer-reviewed publications in elite journals like Nature Microbiology, 260 citations placing him in the top 1% of his field, and the completion of over 20 peer reviews for high-impact journals.
View Case

Scientist

Biotechnology · Taiwan

WeGreened EB-1A approved
New Jersey 16 days 2025-12-24
The petition was approved based on 6 peer-reviewed journal articles and a citation record placing the petitioner in the top 1% of highly cited authors in the delivery-systems space. Additionally, the petitioner demonstrated peer recognition through 6 completed journal reviews and received competitive support from the National Science and Technology Council of Taiwan. These metrics satisfied the EB-1A requirements for original contributions, scholarly articles, and judging.
View Case

Frequently Asked Questions

A approved EB-1A (I-140) petition means USCIS determined the petitioner met the eligibility requirements. For appealed cases, "sustained" means the appeal reversed a prior denial. The petitioner can proceed to the next step in the immigration process.

Browse More Cases

More approved cases More Pharmaceuticals cases More cases from India

Case data sourced from publicly available petition decisions and case studies. Decision date: 2025-09-18.

Browse all cases
View Original

At a Glance

Outcome approved
Processing 116 days
RFE Issued
Criteria Met 3 / 3
Evidence Types 8

EB-1A Case Data

Scraped Case Data

Total Cases 919
Success Rate 53.0%
Sustained 487
Dismissed 315

Related Pages

EB-1A Overview EB-1A in India All EB-1A Cases EB-1A Dashboard

Get Case Insights

Compare your profile against thousands of real petition outcomes. Join the waitlist for personalized analysis.

Join Waitlist